Implant Sciences Corporation, a high technology supplier of systems and sensors for homeland security and defense markets, today stated that it has shipped over $600,000 in previously unannounced orders of QS-H150 and QS-B220s to multiple customers in Europe, the Middle East, and Africa. Customers for the handheld and desktop explosives trace detectors include airports, cargo companies, hotels, and petroleum industry facilities.
"These shipments include orders that are a direct result of the impressive list of certifications our QS-B220 has received in the last year. Implant Sciences continues to increase its presence in the aviation security market, and overall, about half of the units shipped went to aviation security users," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones.
"Over the years, Implant Sciences' products have garnered a lot of respect in the market segments we have served. For example, one of these recent shipments is the fifth order from one of our critical infrastructure customers," added Glenn D. Bolduc, President and CEO at Implant Sciences. "As we expand our presence in the large aviation security market, we look forward to building the same kind of success there."
About the QS-H150 Handheld Explosives Trace Detector
The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.
About the QS-B220 Desktop Explosives and Drugs Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as illicit drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
Source: http://www.implantsciences.com/